MCID: BRC012
MIFTS: 70

Brucellosis

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Brucellosis

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 76 53 59 55 3 44 15 73
Undulant Fever 12 53 3
Mediterranean Fever 12 76
Gibraltar Fever 12 53
Malta Fever 12 53
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 53
Rock Fever 53

Characteristics:

Orphanet epidemiological data:

59
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11077
ICD9CM 35 023 023.9
MeSH 44 D002006
NCIt 50 C84602
Orphanet 59 ORPHA1304
ICD10 via Orphanet 34 A23.3 A23.8 A23.9 more
UMLS via Orphanet 74 C0006309
MESH via Orphanet 45 D002006
UMLS 73 C0006309

Summaries for Brucellosis

NIH Rare Diseases : 53 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis, swelling of the testicle and scrotum, swelling of the heart (endocarditis), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases.

MalaCards based summary : Brucellosis, also known as undulant fever, is related to familial mediterranean fever and amyloidosis aa, and has symptoms including fever, sweat and headache. An important gene associated with Brucellosis is MEFV (MEFV, Pyrin Innate Immunity Regulator), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Abatacept and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include heart, breast and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

Wikipedia : 76 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Related Diseases for Brucellosis

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 479)
# Related Disease Score Top Affiliating Genes
1 familial mediterranean fever 32.2 CRP IL1RN MEFV SAA1 TNF
2 amyloidosis aa 31.3 CRP MEFV SAA1
3 purpura 30.4 CD40LG CRP TNF
4 cat-scratch disease 30.4 CD40LG IFNG
5 listeriosis 30.4 IL10 IL6 TNF
6 campylobacteriosis 30.3 IFNG SLC11A1 TLR4
7 acalculous cholecystitis 30.3 CD40LG CRP
8 tuberculous peritonitis 30.3 CRP IFNG TNF
9 q fever 30.2 CD40LG IFNG IL10 TLR4 TNF
10 infective endocarditis 30.2 CRP IL6 TNF
11 myocarditis 30.1 CD40LG IL6 TNF
12 granulomatous hepatitis 30.0 CD40LG CRP IL4
13 spondyloarthropathy 1 30.0 CD40LG CRP TNF
14 legionellosis 30.0 CD40LG TLR4 TNF
15 capillary leak syndrome 30.0 CXCL8 IL2 IL6
16 salmonellosis 30.0 IFNG SLC11A1 TLR4
17 demyelinating disease 29.9 CD40LG IFNG IL10 TNF
18 extrapulmonary tuberculosis 29.8 IFNG IL10 IL1RN SLC11A1
19 pertussis 29.7 IL10 IL6 TLR4 TNF
20 transverse myelitis 29.6 CXCL8 IL10 IL6 TNF
21 melioidosis 29.6 IFNG IL10 IL6 TLR4 TNF
22 endocarditis 29.6 CRP CXCL8 IL10 IL6 TNF
23 hemorrhagic fever 29.5 CD40LG IFNG IL10 IL6 TNF
24 acute pyelonephritis 29.5 CRP CXCL8 IL10 IL6
25 reactive arthritis 29.4 CRP IFNG IL10 IL6 TNF
26 acute pancreatitis 29.4 CRP CXCL8 IL10 IL6
27 septic arthritis 29.3 CRP CXCL8 IFNG TLR4
28 leptospirosis 29.3 CD40LG CRP CXCL8 IL10 IL6 TNF
29 spondylitis 29.2 CD40LG CRP IL1RN IL6 TNF
30 prostatitis 28.9 CXCL8 IL10 IL2 IL6 TNF
31 hemophagocytic lymphohistiocytosis 28.9 CXCL8 IFNG IL10 IL2RA TNF
32 uveitis 28.9 IFNG IL10 IL2RA IL4 TNF
33 pericarditis 28.8 CRP IL6 MEFV TNF
34 pharyngitis 28.8 CRP CXCL8 MEFV
35 toxoplasmosis 28.7 CD40LG IFNG IL10 IL4 IL6 TLR4
36 typhoid fever 28.7 CRP IFNG IL6 SLC11A1 TLR4 TNF
37 vasculitis 28.7 CD40LG CRP MEFV TNF
38 meningitis 28.5 CD40LG CRP CXCL8 IFNG IL10 IL6
39 pyelonephritis 28.4 CRP CXCL8 IL10 IL6 TLR4 TNF
40 exanthem 28.2 CD40LG CRP IL1RN IL2 IL6 TNF
41 helicobacter pylori infection 28.1 CXCL8 IFNG IL10 IL1RN TLR4 TNF
42 trypanosomiasis 28.0 CXCL8 IFNG IL10 IL2 IL4 IL6
43 pneumonia 27.9 CD40LG CRP CXCL8 IL10 IL6 TLR4
44 arthritis 27.8 CXCL8 IFNG IL10 IL1RN IL6 SAA1
45 peritonitis 27.8 CRP CXCL8 IL10 IL6 MEFV TNF
46 chlamydia 27.5 CD40LG CRP CXCL8 IFNG IL10 IL6
47 autoimmune disease 26.3 CD40LG IFNG IL10 IL1RN IL2 IL2RA
48 familial mediterranean fever, autosomal dominant 12.4
49 brucella melitensis brucellosis 12.3
50 brucella abortus brucellosis 12.3

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis

Symptoms & Phenotypes for Brucellosis

Symptoms:

12
  • fever
  • sweat
  • headache
  • back pain
  • physical weakness
  • joint pain
  • fatigue

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 TNF CD40LG CXCL8 IL10 IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 TNF CD40LG CXCL8 IL10 IL2 IL2RA

MGI Mouse Phenotypes related to Brucellosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.29 IL2 IL2RA IL4 IL6 MEFV SAA1
2 hematopoietic system MP:0005397 10.27 CD40LG IFNG IL10 IL1RN IL2 IL2RA
3 immune system MP:0005387 10.27 SLC11A1 TLR4 TNF CD40LG CRP IFNG
4 cellular MP:0005384 10.25 CD40LG IFNG IL10 IL1RN IL2 IL4
5 cardiovascular system MP:0005385 10.21 IL1RN IL2 IL6 TLR4 TNF CD40LG
6 growth/size/body region MP:0005378 10.21 IL4 IL6 MEFV TLR4 TNF IFNG
7 digestive/alimentary MP:0005381 10.19 IFNG IL10 IL2 IL2RA IL4 IL6
8 mortality/aging MP:0010768 10.15 IL2RA IL4 IL6 MEFV SLC11A1 TLR4
9 endocrine/exocrine gland MP:0005379 10.13 CD40LG IFNG IL10 IL2 IL2RA IL4
10 integument MP:0010771 10.09 TNF CD40LG IFNG IL10 IL1RN IL4
11 liver/biliary system MP:0005370 10.01 IFNG IL10 IL2 IL4 IL6 MEFV
12 reproductive system MP:0005389 9.96 CD40LG IFNG IL10 IL1RN IL2 IL4
13 neoplasm MP:0002006 9.87 IFNG IL10 IL2 IL6 SLC11A1 TLR4
14 respiratory system MP:0005388 9.76 IFNG IL10 IL2 IL2RA IL4 IL6
15 skeleton MP:0005390 9.61 CD40LG IFNG IL10 IL1RN IL4 IL6
16 vision/eye MP:0005391 9.23 IFNG IL10 IL2 IL2RA IL4 IL6

Drugs & Therapeutics for Brucellosis

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 775)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
5
Atenolol Approved Phase 4,Not Applicable 29122-68-7 2249
6
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
7
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
8
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
9
Sertraline Approved Phase 4,Not Applicable 79617-96-2 68617
10
Methyltestosterone Approved Phase 4,Phase 3,Not Applicable 58-18-4 6010
11
Testosterone Approved, Investigational Phase 4,Phase 3,Not Applicable 58-22-0 6013
12
Testosterone enanthate Approved Phase 4,Phase 3,Not Applicable 315-37-7 9416
13
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Not Applicable 5949-44-0
14
Heroin Approved, Illicit, Investigational Phase 4 561-27-3 5462328
15
Naloxone Approved, Vet_approved Phase 4,Not Applicable 465-65-6 5284596
16
Cobicistat Approved Phase 4 1004316-88-4
17
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
18
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
19
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-86-8 6167 2833
20
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable 58-61-7 60961
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
22
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3 376348-65-1 3002977
23
Regadenoson Approved, Investigational Phase 4,Not Applicable 313348-27-5 219024
24
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
25
Telavancin Approved Phase 4 372151-71-8
26
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
27
Oseltamivir Approved Phase 4,Phase 3 204255-11-8, 196618-13-0 65028
28
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
29
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
30
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
31
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
32
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
33
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
34
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
35
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
36
Donepezil Approved Phase 4,Phase 2 120014-06-4 3152
37
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
38
Febuxostat Approved Phase 4,Phase 2 144060-53-7 134018
39
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
40
Amodiaquine Approved, Investigational Phase 4,Phase 3 86-42-0 2165
41
Artesunate Approved, Investigational Phase 4,Phase 3 88495-63-0 6917864 5464098
42
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
43
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
44
Dapsone Approved, Investigational Phase 4 80-08-0 2955
45
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
46
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
47
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 1302 156391
48
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
49
Ramipril Approved Phase 4 87333-19-5 5362129
50
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999

Interventional clinical trials:

(show top 50) (show all 1005)
# Name Status NCT ID Phase Drugs
1 VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department Unknown status NCT00468065 Phase 4
2 Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression Unknown status NCT01875224 Phase 4 Belatacept;Tacrolimus
3 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
4 Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers Unknown status NCT01492140 Phase 4
5 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
6 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
7 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4 Intranasal (IN) naloxone;Intravenous (IV) naloxone;Intramuscular (IM) naloxone;Intraosseus (IO) naloxone
8 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
9 Sleep and Cognition After Atripla to Stribild Switch Unknown status NCT02283060 Phase 4 Stribild;Atripla
10 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
11 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed NCT01449006 Phase 4 Maraviroc
12 Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET Completed NCT01109992 Phase 4 Exercise plus Regadenoson (Lexercise);Regadenoson (Lexiscan)
13 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) Completed NCT00663403 Phase 4 Daptomycin
14 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed NCT02392208 Phase 4 Telavancin
15 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation Completed NCT00578968 Phase 4 Tiotropium;Placebo
16 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
17 Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) Completed NCT01048879 Phase 4
18 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis Completed NCT00877370 Phase 4 ertapenem
19 The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems Completed NCT00988117 Phase 4 Rivastigmine Patch 9.5 cm2
20 Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
21 Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS) Completed NCT00263393 Phase 4 ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
22 Helping Those With Mental Illness Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
23 Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures Completed NCT01376960 Phase 4
24 ULTRA Study for Pacemaker Patients Completed NCT00133289 Phase 4
25 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed NCT00224289 Phase 4 Latanoprost 0.005%
26 Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
27 Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer Completed NCT00950053 Phase 4
28 Needle Length In Obese Insulin-Using Diabetic Subjects Completed NCT00541372 Phase 4
29 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed NCT00177671 Phase 4 Escitalopram;Donepezil;Venlafaxine;Placebo;Duloxetine
30 Foot and Ankle Clinic Application for Liposomal Related Anesthetic Completed NCT02586077 Phase 4 Exparel
31 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
32 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
33 Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia Completed NCT01844102 Phase 4
34 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4 Febuxostat;Febuxostat placebo
35 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
36 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
37 Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Completed NCT00531947 Phase 4 Selegiline Transdermal System;Placebo
38 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
39 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
40 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen
41 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. Completed NCT00153101 Phase 4 Telmisartan;Combination of Telmisartan and Ramipril;Ramipril
42 Corticosteroids With Vedolizumab in Crohn's Disease Recruiting NCT02324699 Phase 4 Prednisone;Placebo;Vedolizumab
43 Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Recruiting NCT02699645 Phase 4 telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;Placebo
44 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
45 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
46 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure Recruiting NCT02787044 Phase 4
47 Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study Recruiting NCT02202369 Phase 4
48 A Prospective Study of the InterFuse T(tm), Recruiting NCT02678130 Phase 4
49 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
50 Zoster Eye Disease Study Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Genetic Tests for Brucellosis

Anatomical Context for Brucellosis

MalaCards organs/tissues related to Brucellosis:

41
Heart, Breast, Testes, Lung, Prostate, Liver, Bone

Publications for Brucellosis

Articles related to Brucellosis:

(show top 50) (show all 1765)
# Title Authors Year
1
Knowledge, attitudes, and practices (KAP) related to brucellosis and factors affecting knowledge sharing on animal diseases: a cross-sectional survey in the dry zone of Sri Lanka. ( 29392550 )
2018
2
First case of cervical epidural abscess caused by brucellosis in Saudi Arabia: A case report and literature review. ( 29682450 )
2018
3
Angiotensin Converting Enzyme Gene Insertion/Deletion Variant and Familial Mediterranean Fever-related Amyloidosis. ( 29891744 )
2018
4
A rare cause of fever in an adult: a case of familial Mediterranean fever. ( 29559814 )
2018
5
Association between human brucellosis and adverse pregnancy outcome: a cross-sectional population-based study. ( 29344838 )
2018
6
Congenital Brucellosis: A Systematic Review of the Literature. ( 29957148 )
2018
7
Transplantation within the era of anti il-1 therapy: case series of 5 patients with familial mediterranean fever related amyloidosis. ( 29957882 )
2018
8
Consequences of brucellosis infection during pregnancy: A systematic review of the literature. ( 29885371 )
2018
9
Effects of mating patterns on genealogical trees: Assessment of the high carrier rate of Familial Mediterranean Fever in rural Israeli districts. ( 29382538 )
2018
10
Blood group 'A' may have a possible modifier effect on familial Mediterranean fever and blood group '0' may be associated with colchicine resistance. ( 29873519 )
2018
11
Case report: acute hydrops and spontaneous corneal perforation in a patient with keratoconus treated with colchicine for familial Mediterranean fever. ( 29713855 )
2018
12
Very Rare Presentation of Cerebrovascular Accident in 20-Year-Old Man With Familial Mediterranean Fever-Case Report. ( 29326535 )
2018
13
A 44-Year-Old Female with Familial Mediterranean Fever, Cardiomyopathy and End Stage Renal Disease. ( 29265632 )
2018
14
The microRNA expression signature of CD4+ T cells in the transition of brucellosis into chronicity. ( 29897958 )
2018
15
Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report. ( 29427095 )
2018
16
Atypical familial Mediterranean fever developed in a long-term hemodialysis patient. ( 29345845 )
2018
17
Trend Analysis and Affecting Components of Human Brucellosis Incidence During 2006 to 2016. ( 29416212 )
2018
18
Lack of clear and univocal genotype-phenotype correlation in Familial Mediterranean Fever patients: A systematic review. ( 29393966 )
2018
19
Epidemiological, Clinical and Molecular Characterization of Human Brucellosis in Bosnia and Herzegovina - An Ongoing Brucellosis Outbreak. ( 29957971 )
2018
20
Sacroiliitis in Children With Familial Mediterranean Fever. ( 29596210 )
2018
21
Chemotherapy-Colchicine Interaction in a Child with Familial Mediterranean Fever and Hodgkin Lymphoma. ( 29531656 )
2018
22
The detection of brucellosis antibody in whole serum based on the low-fouling electrochemical immunosensor fabricated with magnetic Fe<sub>3</sub>O<sub>4</sub>@Au@PEG@HA nanoparticles. ( 29894850 )
2018
23
Fatigue in pediatric patients with familial Mediterranean fever. ( 29322855 )
2018
24
Increased psoriasis frequency in patients with familial Mediterranean fever. ( 29363386 )
2018
25
Familial Mediterranean Fever Mutations in a Patient with Periodic Episodes of Systemic Pain Deriving from Cancer Bone Metastases. ( 29780113 )
2018
26
Brucellosis after Cardiac Transplantation. ( 29932889 )
2018
27
Long-term familial Mediterranean fever remission on successful hepatitis C virus treatment in a patient not responding to colchicine: a case report. ( 29773081 )
2018
28
Hematologic Manifestations of Brucellosis in Children. ( 29329166 )
2018
29
Familial Mediterranean Fever: New Insights Into Cancer Immunoprevention? Comment on the Article by Brenner et al. ( 29569856 )
2018
30
Liver involvement is associated with blood culture positivity and high agglutination titre in patients with brucellosis in Turkey. ( 29972349 )
2018
31
Serosurveillance of Coxiellosis (Q-fever) and Brucellosis in goats in selected provinces of Lao People's Democratic Republic. ( 29649313 )
2018
32
Rethinking &amp;quot;One Health&amp;quot; through Brucellosis: ethics, boundaries and politics. ( 29869782 )
2018
33
Myelitis and Polyradiculoneuropathy With Severe Pain: Unusual Neurological Manifestations as Presenting Symptoms of Brucellosis. ( 29953037 )
2018
34
Brucellosis Prevalence in Brazilian Slaughterhouses with Different Meat Inspection Systems. ( 29897272 )
2018
35
Lipid profile and atherogenic indices and their association with platelet indices in familial Mediterranean fever. ( 29664424 )
2018
36
Comparison of early versus late onset familial Mediterranean fever. ( 29314707 )
2018
37
Canakinumab treatment in children with familial Mediterranean fever: report from a single center. ( 29450637 )
2018
38
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
39
Clinical and genetic heterogeneity in a large cohort of Armenian patients with late-onset familial Mediterranean fever. ( 29543225 )
2018
40
Seroprevalence of bovine brucellosis and associated risk factors in Nakasongola district, Uganda. ( 29948776 )
2018
41
First case-control study of zoonotic brucellosis in Gafsa district, Southwest Tunisia. ( 29911160 )
2018
42
Evaluation of three serological tests for diagnosis of bovine brucellosis in smallholder farms in Pakistan by estimating sensitivity and specificity using Bayesian latent class analysis. ( 29290297 )
2018
43
A Case of Familial Mediterranean Fever with Extensive Lymphadenopathy and Complex Heterozygous Genotype Presenting in the Fourth Decade. ( 29808155 )
2018
44
Analysis of microRNAs in familial Mediterranean fever. ( 29787577 )
2018
45
Prevalence of brucellosis among patients attending Wau Hospital, South Sudan. ( 29949605 )
2018
46
An autoimmune disease-associated risk variant in the<i>TNFAIP3</i>gene plays a protective role in brucellosis that is mediated by the NF-kappa B signaling pathway. ( 29343543 )
2018
47
The evaluation of salivary oxidative stress in patients with familial mediterranean fever and chronic periodontitis. ( 29761911 )
2018
48
Abortions in an organized dairy farm from North India reveal the possibility of breed susceptibility to Bovine Brucellosis. ( 29911159 )
2018
49
The sero-prevalence of brucellosis in cattle and their herders in Bahr el Ghazal region, South Sudan. ( 29924843 )
2018
50
Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. ( 29446001 )
2018

Variations for Brucellosis

Expression for Brucellosis

Search GEO for disease gene expression data for Brucellosis.

Pathways for Brucellosis

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CD40LG CRP CXCL8 IFNG IL10 IL1RN
2
Show member pathways
13.74 CD40LG CXCL8 IFNG IL10 IL1RN IL2
3
Show member pathways
13.56 CXCL8 IFNG IL10 IL2 IL2RA IL4
4
Show member pathways
13.47 CD40LG CXCL8 IL10 IL2 IL2RA IL4
5
Show member pathways
13.37 CD40LG CXCL8 IFNG IL10 IL1RN IL2
6
Show member pathways
13.36 CD40LG CXCL8 IL10 IL2 IL2RA IL4
7
Show member pathways
13.11 CXCL8 IFNG IL10 IL2 IL6 MEFV
8
Show member pathways
13.03 IL2 IL2RA IL4 IL6 TLR4 TNF
9
Show member pathways
12.95 CD40LG CXCL8 IFNG IL10 IL2 IL2RA
10
Show member pathways
12.92 IL2 IL2RA IL4 IL6 TNF
11 12.91 CXCL8 IFNG IL2 IL2RA IL4 IL6
12
Show member pathways
12.89 CXCL8 IFNG IL2 IL2RA IL4 IL6
13
Show member pathways
12.87 IFNG IL2 IL2RA IL4 TLR4 TNF
14
Show member pathways
12.85 CXCL8 IFNG IL6 SAA1 TLR4 TNF
15
Show member pathways
12.75 CD40LG IL2 IL6 TLR4 TNF
16
Show member pathways
12.67 CXCL8 IFNG IL10 IL2 IL2RA IL4
17
Show member pathways
12.65 IFNG IL10 IL2 IL6 TNF
18 12.61 CD40LG IFNG IL10 IL1RN IL2 IL2RA
19
Show member pathways
12.57 CXCL8 IL6 TLR4 TNF
20
Show member pathways
12.54 CD40LG IFNG IL10 IL2 IL4 IL6
21
Show member pathways
12.53 IFNG IL2 IL4 TNF
22
Show member pathways
12.46 IFNG IL10 IL2 IL2RA IL4 IL6
23 12.45 IL2 IL2RA IL6 TNF
24
Show member pathways
12.44 CRP IFNG IL2 IL4 IL6 SAA1
25
Show member pathways
12.43 CXCL8 IFNG IL4 IL6 TNF
26
Show member pathways
12.38 CXCL8 IFNG IL6 TLR4 TNF
27
Show member pathways
12.38 IFNG IL10 IL2 IL6 TLR4 TNF
28
Show member pathways
12.38 CD40LG IFNG IL10 IL4 TLR4 TNF
29 12.34 IFNG IL10 IL6 TLR4 TNF
30
Show member pathways
12.32 CXCL8 IL6 TLR4 TNF
31
Show member pathways
12.3 CXCL8 IFNG IL4 IL6 TLR4 TNF
32 12.29 CXCL8 IL10 IL1RN IL6 TNF
33
Show member pathways
12.28 CXCL8 IL1RN IL6 TNF
34
Show member pathways
12.27 IL10 IL2 IL6 TNF
35 12.24 IFNG IL6 TLR4 TNF
36
Show member pathways
12.19 CXCL8 IFNG IL10 IL2 IL2RA IL4
37 12.11 CXCL8 IL10 IL4 IL6 SAA1 TNF
38
Show member pathways
12.07 IFNG IL2 IL2RA IL4
39 12.02 IFNG IL10 IL2 IL2RA IL6
40 12.01 CXCL8 IFNG IL10 IL6 TLR4 TNF
41 12 IL2RA IL4 IL6 TNF
42 12 CXCL8 IFNG IL6 TLR4 TNF
43 11.99 CD40LG CXCL8 TLR4 TNF
44 11.99 CXCL8 IFNG IL2 IL4 IL6 TLR4
45 11.96 CXCL8 IFNG IL6
46 11.95 CXCL8 IFNG IL2 IL4 IL6
47 11.94 CXCL8 IFNG IL6 TLR4
48 11.93 IFNG IL6 TLR4
49 11.93 IFNG IL10 IL2 IL2RA IL4 IL6
50 11.92 CXCL8 IL6 TNF

GO Terms for Brucellosis

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.81 CD40LG CXCL8 IFNG IL1RN IL2 IL2RA
2 extracellular region GO:0005576 9.7 CD40LG CRP CXCL8 IFNG IL10 IL1RN
3 external side of plasma membrane GO:0009897 9.56 CD40LG IL2RA TLR4 TNF
4 extracellular space GO:0005615 9.36 CD40LG CRP CXCL8 IFNG IL10 IL1RN

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 CRP IFNG IL6 SLC11A1 TLR4 TNF
2 defense response to bacterium GO:0042742 9.97 IL10 SLC11A1 TLR4 TNF
3 response to lipopolysaccharide GO:0032496 9.96 CXCL8 IL10 SLC11A1 TLR4
4 regulation of signaling receptor activity GO:0010469 9.91 CD40LG CXCL8 IFNG IL10 IL1RN IL2
5 activation of MAPK activity GO:0000187 9.9 SAA1 TLR4 TNF
6 platelet activation GO:0030168 9.9 CD40LG IL6 SAA1
7 positive regulation of DNA binding transcription factor activity GO:0051091 9.89 IL10 IL6 TNF
8 defense response to Gram-positive bacterium GO:0050830 9.89 CRP IL6 TNF
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.89 CD40LG IL6 TLR4 TNF
10 defense response to Gram-negative bacterium GO:0050829 9.88 IL6 SLC11A1 TLR4
11 B cell differentiation GO:0030183 9.85 CD40LG IL10 IL4
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IFNG IL2 IL6
13 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IL10 IL6 TLR4 TNF
14 humoral immune response GO:0006959 9.83 IFNG IL6 TNF
15 positive regulation of interleukin-6 production GO:0032755 9.82 IL6 TLR4 TNF
16 positive regulation of B cell proliferation GO:0030890 9.81 IL2 IL4 TLR4
17 cytokine-mediated signaling pathway GO:0019221 9.81 CXCL8 IL10 IL1RN IL2 IL2RA IL4
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 IFNG TLR4 TNF
19 response to glucocorticoid GO:0051384 9.8 IL10 IL1RN IL6 TNF
20 acute-phase response GO:0006953 9.78 CRP IL6 SAA1
21 negative regulation of inflammatory response GO:0050728 9.77 IL10 IL2 IL2RA MEFV SAA1
22 positive regulation of cytokine secretion GO:0050715 9.76 IL10 SAA1 TNF
23 negative regulation of interleukin-6 production GO:0032715 9.74 IL10 TLR4 TNF
24 regulation of protein secretion GO:0050708 9.73 SAA1 TNF
25 positive regulation of interleukin-12 production GO:0032735 9.73 CD40LG IFNG TLR4
26 positive regulation of interferon-gamma production GO:0032729 9.73 IL2 SLC11A1 TLR4 TNF
27 immune response GO:0006955 9.73 CD40LG CXCL8 IFNG IL10 IL1RN IL2
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 IFNG TNF
29 positive regulation of macrophage activation GO:0043032 9.72 IL10 TLR4
30 negative regulation of growth of symbiont in host GO:0044130 9.72 IL10 TNF
31 positive regulation of chemokine production GO:0032722 9.72 IL6 TLR4 TNF
32 positive regulation of T cell proliferation GO:0042102 9.72 CD40LG IL2 IL2RA IL4 IL6
33 response to molecule of bacterial origin GO:0002237 9.71 CXCL8 IL10
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
35 positive regulation of immunoglobulin secretion GO:0051024 9.71 IL2 IL6
36 negative regulation of interleukin-12 production GO:0032695 9.71 IL10 MEFV
37 positive regulation of T cell differentiation GO:0045582 9.71 IL2 IL2RA IL4
38 negative regulation of interleukin-17 production GO:0032700 9.7 IFNG TLR4
39 interleukin-2-mediated signaling pathway GO:0038110 9.7 IL2 IL2RA
40 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.7 IL10 IL1RN
41 regulation of regulatory T cell differentiation GO:0045589 9.7 IFNG IL2 IL2RA
42 macrophage activation GO:0042116 9.69 SLC11A1 TLR4
43 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL2 IL4
44 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 TLR4 TNF
45 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
47 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2 IL2RA
48 type 2 immune response GO:0042092 9.66 IL10 IL4
49 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.65 IL1RN IL6
50 regulation of immunoglobulin secretion GO:0051023 9.65 CD40LG TNF

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 CD40LG CXCL8 IFNG IL10 IL1RN IL2
2 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 IL6

Sources for Brucellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN